Neboglamine HCL – (163000-63-3)

Neboglamine, also known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor, currently under investigation by Rottapharm for the treatment of schizophrenia and cocaine dependence. This compound has demonstrated cognition- and memory-enhancing effects in animal models, making it a promising candidate for addressing the cognitive deficits associated with schizophrenia. As of June 2015, neboglamine was in Phase II clinical trials for both schizophrenia and cocaine abuse.

Research indicates that neboglamine significantly increases the number of Fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus, similar to the effects of haloperidol and clozapine. However, unlike these drugs, neboglamine does not affect the basal levels of locomotor activity and has no impact on the dorsolateral striatum. In behavioral models, neboglamine has been shown to inhibit PCP-induced hyperlocomotion and rearing behavior, suggesting its potential as an antipsychotic agent.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Neboglamine
https://www.medchemexpress.com/neboglamine-hydrochloride.html
https://www.medkoo.com/products/12384
https://www.sciencedirect.com/science/article/abs/pii/S1043661809003053
https://pubmed.ncbi.nlm.nih.gov/20045056/
https://drugs.ncats.io/drug/12EA34U5B8